Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Afumati

363 clinical trials in Afumati, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Afumati at a glance
363
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

363 trials in Afumati

Open in trial search

Obesity+1

Recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:HLX43
  • Sponsor:Shanghai Henlius Biotech Inc.

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Afumati

What the registry says about research in the country

01 Autoimmune Research

Innovative clinical research focusing on Systemic Lupus Erythematosus (SLE), evaluating new therapeutic approaches with ianalumab in combination with standard treatments. The trials aim to improve patient response rates and disease management outcomes.

  • SLE Treatment Development
  • Monthly Subcutaneous Therapy
  • Response Index Assessment

These studies represent significant advancement in autoimmune disease research.

02 Cardiovascular Prevention

Groundbreaking research in atherosclerotic cardiovascular disease (ASCVD) prevention, investigating inclisiran's potential in reducing major adverse cardiovascular events in high-risk patients.

  • Primary ASCVD Prevention
  • Cardiovascular Risk Reduction
  • Major Adverse Events Prevention

This research aims to establish new standards in preventive cardiology.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.